Skip to main content

Advertisement

Table 6 Adverse events occurring in at least 5% of patients considered to be possibly related to treatment

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

  Adverse events (% of patients)
  Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
Nausea 36% 38%
Leukopenia 36% 26%
Thrombocytopenia 34% 33%
Anemia 27% 26%
Fatigue 23% 19%
Vomiting 18% 26%
Fever 11% 10%
Shivering 14% 2%
Peripheral edema 9% 5%
Headache 9% 0%
Sweating increased 11% 2%
Asthenia 7% 10%
Edema 7% 5%
Dyspepsia 7% 7%
Anorexia 7% 14%
Hair changes 5% 12%